Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation

類似資料

• The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
  著者:: Del Re, Marzia, 等
  出版事項: (2019)
• The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
  著者:: Del Re, Marzia, 等
  出版事項: (2018)
• Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
  著者:: Cucchiara, Federico, 等
  出版事項: (2020)
• Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
  著者:: Martina Ruglioni, 等
  出版事項: (2025-02-01)
• Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report
  著者:: Bruno, Rossella, 等
  出版事項: (2017)